Recent Updates
Recently added Catalysts
IPSC Positive Sentiment Score: 75/100

Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Key Takeaway: Century Therapeutics (NASDAQ: IPSC) announced its upcoming participation in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit. The management team will engage in a virtual fireside chat and participate in a panel discussion focusing on advances in manufacturing for next-generation cell therapies. The events are scheduled for April 30, 2024, and will be available for replay on the company's website. This involvement emphasizes Century's commitment to innovating curative therapies for cancer and autoimmune diseases using iPSC technology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prestigious industry summit highlights company's expertise.
  • Focus on iPSC-derived cell therapies signals innovation in treatment options.
  • Potential to expand patient access to cutting-edge therapies.

Full Press Release Details

PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, details of the presentations are as follows:
Fireside Chat on Tuesday, April 30, 2024, at 1:30pm ET
Panel titled “iPSCs Unleashed: Mastering Manufacturing for Next-Gen Cell Therapies” on Tuesday, April 30, 2024, at 3:30pm ET
A replay of the events will be available on the “Events & Presentations” page in the “Investors” section of the Company’s website at https://investors.centurytx.com/events-and-presentations and will be available for 90 days following the events.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer and autoimmune and inflammatory diseases that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune and inflammatory diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune and inflammatory disease care. For more information on Century Therapeutics please visit www.centurytx.com.
For More Information:
Investors/Media: Julie Seidel/ Noor Pahlavi – century@argotpartners.com

Frequently Asked Questions

What is Century Therapeutics known for?

Century Therapeutics specializes in iPSC-derived cell therapies for cancer and autoimmune diseases.

When is the fireside chat scheduled?

The fireside chat will take place on April 30, 2024, at 1:30 PM ET.

Where can I watch the replay of the events?

Replays will be available on the Company’s 'Events & Presentations' page for 90 days.

What is the focus of the panel discussion?

The panel will discuss mastering manufacturing for next-gen cell therapies.

How is Century Therapeutics advancing cell therapies?

They are enhancing therapies through cellular reprogramming and genetic engineering.

Last updated: Apr 23, 2024